miR-183 as a molecular and protective biomarker for cancer in schizophrenic subjects

Rizos,E.; Siafakas,N.; Koumarianou,A.; Katsantoni,E.; Filippopoulou,A.; Ntounas,P.; Touloumis,Ch.; Kastania,A.; Zoumpourlis,V.

doi:10.3892/or.2012.2052

miR-183 as a molecular and protective biomarker for cancer in schizophrenic subjects

Authors:
- E. Rizos
- N. Siafakas
- A. Koumarianou
- E. Katsantoni
- A. Filippopoulou
- P. Ntounas
- Ch. Touloumis
- A. Kastania
- V. Zoumpourlis
View Affiliations

Affiliations: Second Department of Psychiatry, University General Hospital ‘Attikon’, Medical School, National and Kapodistrian University of Athens, Athens, Greece, Microbiology Laboratory, University General Hospital ‘Attikon’, Medical School, National and Kapodistrian University of Athens, Athens, Greece, Medical Oncology Unit, Second Department of Internal Medicine - Propaedeutic, University General Hospital ‘Attikon’, Athens, Greece, Division of Hematology-Oncology, Biomedical Research Foundation, Academy of Athens, Athens, Greece, Fifth Psychiatric Department, Psychiatric Hospital of Attika, Athens, Greece, Bioinformatics and Medical Informatics Team, Biomedical Research Foundation, Academy of Athens, Athens, Greece, Unit of Biomedical Applications, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece
Published online on: September 21, 2012 https://doi.org/10.3892/or.2012.2052
Pages: 2200-2204

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have suggested that schizophrenia is associated with a reduced risk of cancer. Genes that are involved in cell cycle regulation seem to have additional functions in post-mitotic neurons involved in neuronal migration and synaptic plasticity. MicroRNAs (miRNAs) play a dominant role in the regulation of gene expression in the central nervous system (CNS). Due to their involvement in a large number of CNS pathways, miRNAs pose as appealing molecules for further investigation, with potential diagnostic, prognostic and therapeutic value. In the present study, we investigated the potential association between cancer and schizophrenia in 2 patient sample groups. We analyzed a large number of miRNAs in a control group of 6 schizophrenic patients and a study group of 8 schizophrenic patients with a solid tumor. A comparison between the control and study groups showed that only miR-183 was differentially expressed. Specifically, a significant downregulation of miR-183 in the samples of the study group was observed. Although a larger sample size is required to validate this result for the general patient population, our findings provide a first indication that miR-183 may play a role in regulating the expression of other genes with onco-suppressor activity. Our results are in agreement with the theory that patients with schizophrenia may have a tumor suppressor gene or enhanced neuronal apoptotic activities. Further studies are required in order to shed light on the role of miRNAs and particularly, on the suppressive role of miR-183 in the neurobiological pathways involved in schizophrenia.

View Figures

View References

1	Mortensen PB: The incidence of cancer in schizophrenic patients. J Epidemiol Commun Health. 43:43–47. 1989. View Article : Google Scholar : PubMed/NCBI
2	Lawrence D, Holman CD, Jablenski AV, Threlfall TJ and Fuller SA: Excess cancer mortality in Western Australian psychiatric patients due to higher case fatality rates. Acta Psychiatr Scand. 101:382–388. 2000. View Article : Google Scholar
3	Barak Y, Achiron A, Mandel M, Mirecki I and Aizenberg D: Reduced cancer incidence among patients with schizophrenia. Cancer. 104:2817–2821. 2005. View Article : Google Scholar : PubMed/NCBI
4	Leucht S, Bunkard T, Henderson J, Maj M and Sartorius N: Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 116:317–333. 2007. View Article : Google Scholar : PubMed/NCBI
5	Chou FHC, Tsai KY, Su CY and Lee CC: The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. Schizophr Res. 129:97–103. 2011.PubMed/NCBI
6	Lin GM, Chen YJ, Kuo DJ, Jaiteh LES, Wu YC, Lo TS and Li YH: Cancer incidence in patients with schizophrenia or bipolar disorder: a nationwide population-based study in Taiwan, 1997–2009. Schizophr Bull. 1:1–10. 2011.
7	Fanous AH and Kendler KS: Genetic heterogeneity, modifier genes, and quantitative phenotypses in psychiatric illness: searching for a framework. Mol Psychiatry. 10:6–13. 2005. View Article : Google Scholar : PubMed/NCBI
8	Feinberg AP and Tycko B: The history of cancer epigenetics. Nat Rev Cancer. 4:143–153. 2004. View Article : Google Scholar
9	Rybakowski JK, Skibinska M, Kapelski P, Kaczmarek L and Hauser J: Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia. Schizophr Res. 109:90–93. 2009. View Article : Google Scholar : PubMed/NCBI
10	Catts VS and Catts SV: Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene? Schizophr Res. 41:405–415. 2000. View Article : Google Scholar : PubMed/NCBI
11	Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
12	Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F and Croce CM: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukaemia. Proc Natl Acad Sci USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI
13	Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T and Takahashi T: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
14	Hansen T, Olsen L, Lindow M, Jakobsen K, Ullum H, Jonsson E, Adreassen O, Djurovic S, Melle I, Agartz I, Hall H, Timm S, Wang AG and Werge T: Brain expressed microRNAs implicated in schizophrenia etiology. Plos One. 9:1–7. 2007.
15	Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, Scott RJ, Tran N, Dedova I and Cairns MJ: Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Human Mol Genet. 17:1156–1168. 2008. View Article : Google Scholar : PubMed/NCBI
16	First MB, Spitzer RL, Gibbon M and William JBM: Structured Clinical Interview for DSM-IV Axis I Disorders Patient edition. New York State Psychiatric Institute, Biometrics Research; New York: 1997
17	Kay SR, Opler LA and Lindenmayer JP: The Positive and Negative Syndrome Scale (PANSS): rational and standardization. Br J Psychiatry. 155(Suppl): 59–65. 1987.
18	Cui DH, Jiang KD, Jiang SD, Xu YF and Yao H: The tumor suppressor adenomatous polyposis coli gene is associated with susceptibility to schizophrenia. Mol Psychiatry. 10:669–677. 2005. View Article : Google Scholar : PubMed/NCBI
19	Lichtermann D, Ekelund J, Pukkala E, Tanskanen A and Lonnqvist J: Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry. 58:573–578. 2001. View Article : Google Scholar : PubMed/NCBI
20	Dalton SO, Johansen C, Poulsen AH, Norgaard M, Sorensen HT, McLaughlin JK, Mortensen PB and Friis S: Cancer risk among users of neuroleptic medication: a population-based cohort study. Br J Cancer. 95:934–939. 2006. View Article : Google Scholar : PubMed/NCBI
21	Cao X, Yeo G, Muotri AR, Kuvabara T and Gage FH: Noncoding RNAs in the mammalian central nervous system. An Rev Neurosci. 29:77–103. 2006. View Article : Google Scholar : PubMed/NCBI
22	Lima RT, Busacca S, Almeida GM, Gaudino G, Fennel DA and Vasconcelos MH: MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer. 47:163–174. 2011. View Article : Google Scholar : PubMed/NCBI
23	Cho WC: MicroRNAs in cancer - from research to therapy. Biochim Biophys Acta. 1805:209–217. 2010.PubMed/NCBI
24	Fu LI, Wen X, Bao JK and Liu B: MicroRNA-modulated autophagic signaling networks in cancer. Int J Biochem Cell Biol. 44:733–736. 2012. View Article : Google Scholar : PubMed/NCBI
25	Kim A, Reimers M, Maher B, Williamson V, McMichael O, McClay J, van den Oord E, Riley B, Kendler K and Vladimirov V: MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr Res. 124:183–191. 2010. View Article : Google Scholar : PubMed/NCBI
26	Li ZY, Yang Y, Ming M and Liu B: Mitochondrial ROS generation for regulation of autophagic pathways in cancer. Biochem Biophys Res Commun. 414:5–8. 2011. View Article : Google Scholar : PubMed/NCBI
27	Jian X, Xiao-yan Z, Bin H, Yu-feng Z, Bo K, Zhi-nong W and Xin N: Mir-204 regulate cardiomyocyte autophagy induced by hypoxia-reoxygenetion through LC3-II. Int J Cardiol. 148:111–112. 2011. View Article : Google Scholar : PubMed/NCBI
28	Abraham D, Jackson N, Gundara JS, Zhao J, Gill AJ, Delbridge L, Robinson BG and Sidhu SB: MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res. 17:4772–4781. 2011. View Article : Google Scholar
29	Wang G, Mao W and Zheng S: MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett. 582:3663–3668. 2008. View Article : Google Scholar : PubMed/NCBI
30	Sarver A, Li L and Subramanian S: MicroRNA miR-183 functions as an oncogene by targeting the transcriptional factor ERG1 and promoting tymor cell migration. Cancer Res. 70:9570–9580. 2010. View Article : Google Scholar : PubMed/NCBI
31	Babashah S and Soleimani M: The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer. 47:1127–1137. 2011. View Article : Google Scholar : PubMed/NCBI
32	Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang X and Wang L: Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol. 180:2440–2451. 2012. View Article : Google Scholar : PubMed/NCBI
33	Li J, Liang S, Jin H, Xu C, Ma D and Lu X: Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells. Oncol Rep. 27:1835–1842. 2012.PubMed/NCBI
34	Hermeking H: P53 enters the microRNA world. Cancer Cell. 12:414–418. 2007. View Article : Google Scholar : PubMed/NCBI
35	Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). JBC. 282:14328–14336. 2007. View Article : Google Scholar : PubMed/NCBI
36	Frankel LB, Christoffersen NR, Jakobsen A, Lindow M, Krogh A and Lund AH: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 283:1026–1033. 2008. View Article : Google Scholar : PubMed/NCBI
37	Perkins DO, Jeffries CD, Jarskog LF, Thomson JM, Woods K, Newman MA, Parker JS, Jim JP and Hammond SM: MicroRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol. 8:R272007. View Article : Google Scholar : PubMed/NCBI
38	Abu-Elneel K, Liu T, Gazzaniga FS, Nishimura Y, Wall DP, Geschwind DH, Lao K and Kosik KS: Heterogenous dysregulation of microRNAs across the autism spectrum. Neurogenetics. 9:153–161. 2008. View Article : Google Scholar : PubMed/NCBI
39	Junn E, Lee KW, Jeong BS, Chan TW, Imb J and Mouradian MM: Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci USA. 106:13052–13057. 2009. View Article : Google Scholar : PubMed/NCBI
40	Cogswell JP, Ward J, Taylor A, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD and Richards CA: Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimer Dis. 14:27–41. 2008.